1-3 of 3
Saskia Neuteboom, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 1 Clinical Trial of the Novel Structure Proteasome Inhibitor NPI-0052.

Andrew Spencer, Michael Millward, MD, Paul Mainwaring, MD, Simon Harrison, MD, Laurence Catley, MBBS, FRCPA, FRACP, Amanda Townsend, MD, Shawgi Sukumaran, MD, Angie M. Longenecker, RN, BSN, Michael A. Palladino, PhD, G. Kenneth Lloyd, PhD, Saskia Neuteboom, PhD, Peeter Padrik, MD, Matthew A. Spear, MD, Timothy Price, MD
Journal: Blood
Blood (2009) 114 (22): 2693.
https://doi.org/10.1182/blood.V114.22.2693.2693
Published: 2009
Journal Articles

Phase 1 Clinical Trial of the Novel Structure Proteasome Inhibitor NPI-0052 in Patients with Relapsed and Relapsed/Refractory Multiple Myeloma (MM).

Paul Richardson, M.D, Craig Hofmeister, MD, Andrzej Jakubowiak, MD, PhD, Todd M. Zimmerman, MD, Matthew A. Spear, MD, Michael A. Palladino, PhD, Angie M. Longenecker, RN, BSN, Susan L. Kelly, MD, Saskia Neuteboom, PhD, Gillian F Cropp, MSc, G. Kenneth Lloyd, PhD, Alison L. Hannah, MD, Kenneth C. Anderson, MD
Journal: Blood
Blood (2009) 114 (22): 431.
https://doi.org/10.1182/blood.V114.22.431.431
Published: 2009
Journal Articles

The Novel, Orally Active Proteasome Inhibitor, NPI-0052, Induces Apoptosis in Leukemia Lymphoma Cell Lines and Patient Specimens.

Claudia P. Miller, MS, Kechen Ban, PhD, Stacey L. Ruiz, Saskia Neuteboom, PhD, Michael Palladino, PhD, David McConkey, PhD, Joya Chandra, PhD
Journal: Blood
Blood (2005) 106 (11): 241.
https://doi.org/10.1182/blood.V106.11.241.241
Published: 2005